Edit
Civitas Therapeutics
http://civitastherapeutics.com/Last activity: 01.06.2015
Active - Reference to Acorda Therapeutics
Developing and commercializing transformative therapeutics for treating Parkinson’s disease. (ACQR, Acquired by Acorda Therapeutics)
Total raised: $113M
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnova.... |
| - | Bay City C... | baycitycap... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.08.2014 | Series C | $55M | - |
| 11.09.2013 | Series B | $38M | - |
| 10.01.2011 | Series A | $20M | - |
Mentions in press and media 12
| Date | Title | Description |
| 01.06.2015 | Merus Appoints Mark Iwicki as President of the Supervisory Board | Utrecht, The Netherlands — Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as President of its Supervisory Board. “We welcome M... |
| 09.01.2015 | Irish VC Fountain Healthcare launches $127.5M fund | –Chrono Therapeutics, a Bay Area digital smoking cessation startup –Innocoll, an Irish maker of biodegradable surgical implants and topical adhesives to treat post-op pain and diabetic foot ulcers. Its previous investments include: –Civitas... |
| 22.10.2014 | Civitas Therapeutics Acquired by Acorda Therapeutics | Ardsley, NY — Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it has completed its acquisition of Civitas Therapeutics and obtained global rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson’s disease. Th... |
| 26.08.2014 | Civitas Therapeutics Completes $55M Series C Financing | Civitas Therapeutics, Inc., a Chelsea MA-based biopharmaceutical company developing and commercializing therapeutics using its proprietary technology, completed a $55m Series C financing. Backers included new investors Adage Capital Managem... |
| 26.08.2014 | Civitas Therapeutics Closes $55M Series C Fund | CHELSEA, MA, Civitas Therapeutics, Inc, today announced the successful completion of a $55 million Series C financing. >> Click here for more funding data on Civitas Therapeutics >> To export Civitas Therapeutics funding dat... |
| 25.08.2014 | Civitas Therapeutics Secures $55 Million in Series C Financing | Chelsea, MA — Civitas Therapeutics, Inc., a privately-held biopharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced the successful completion of a $55 mil... |
| 28.04.2014 | Civitas Therapeutics Announces Positive Phase 2b Results for CVT-301, Inhaled Levodopa for the Treatment of Parkinson’s Disease | – CVT-301 shown to rapidly treat debilitating OFF episodes associated with Parkinson’s disease– – Met primary endpoint with clinically important and statistically-significant reduction in average UPDRS III motor score versus placebo– – Ph... |
| 11.09.2013 | Civitas Therapeutics Completes $38M Series B Financing | Civitas Therapeutics, Inc., a Chelsea, Mass.-based biopharmaceutical company with a lead program in Parkinson’s disease, completed a $38m Series B financing. The round was led by Bay City Capital with participation from new investors RA Cap... |
| 11.09.2013 | Civitas Therapeutics Lands $38M in Series B | CHELSEA, MA, Biopharmaceutical company with a lead program in Parkinson's disease announced the successful completion of a $38 million Series B financing. >> Click here for more funding data on Civitas Therapeutics >> To exp... |
| 11.09.2013 | Civitas Therapeutics Secures $38 Million in Financing | Chelsea, MA – September 11, 2013 – Civitas Therapeutics, Inc., a biopharmaceutical company with a lead program in Parkinson’s disease that leverages the ARCUS® respiratory delivery platform, today announced the successful completion of a $3... |
Show more